



**CDDF 11TH SPRING
CONFERENCE 2020**
THE NETHERLANDS | 10-12 FEBRUARY 2020



CDDF 11th Spring Conference 2020

10-12 February 2020
Noordwijk aan Zee, Netherlands

Meeting Secretary

Cancer Drug Development Forum

c/o BLSI

Clos Chapelle-aux-Champs 30

1200 Brussels, Belgium

info@cddf.org; hyunmin@cddf.org

Tel: +32 2 880 62 70



EVENT OUTLINE

The Cancer Drug Development Forum (CDDF) Spring conference 2020 is a unique forum that convenes every 18 months and gathers the leaders in the world of innovative cancer therapy development, including medical researchers, pharmaceutical industry representatives, and regulatory authority representatives. Patient representation is also pursued. It is the successor of the former CDDF Alpine Conference and the 11th edition takes place from 10 to 12 February 2020, in Noordwijk aan Zee, the Netherlands. Noordwijk aan Zee is a sea-side village, just 30 minutes from Amsterdam Schiphol Airport.

This multi-stakeholder, interactive meeting offers plenary lectures with moderated discussions, including case studies and networking opportunities.

The programme focuses on the latest and future challenges with a special emphasis on rational combination therapies, tumor agnostic drug development, cell therapy, and the new EMA Anti-cancer Guideline.

PROGRAMME COMMITTEE

- Jaap Verweij (CDDF Board)
- Stefan Schwoch (Lilly)
- Irmela Radtke (Roche)
- Paul Stockman (Astrazeneca)

TARGET AUDIENCE

The target is a multidisciplinary audience of Academia Representatives, EU and US Regulatory Bodies (EMA, FDA, National Agencies), Pharmaceutical Industry, HTAs and patient advocates.

MEETING DATE:

Monday 10 – Wednesday 12 February 2020

MEETING VENUE:

Radisson Blu Hotel, Noordwijk aan Zee in NL

Pickeplein 8, 2202 CL Noordwijk aan Zee, Netherlands

+31 71 365 3000

DRAFT PROGRAMME

(As of 14 August)

DAY 1 - Monday 10 February 2020

12:00 - 13:00 Lunch

Topic 1: THE RELEVANCE OF INDIVIDUAL COMPONENTS IN COMBINATION THERAPIES

13:00-13:30 Pharmacological aspects

13:30-14:00 Clinical trial design aspects

14:00-14:30 Pharma-Industry perspective

14:30-15:00 Regulatory aspects and guidance

15:00-15:30 Coffee Break

Topic 2: REFLECTION ON CDDF WORKSHOPS OF LAST 1,5 YEAR

15:30-15:45 Biomarkers and Patient's access to Personalized Oncology Drugs in Europe

15:45-16:00 Discussion

16:00-16:15 Minimal Residual Disease (AML/CLL)

16:15-16:30 Discussion

16:30-16:45 Impact of Microbiome on Cancer Growth and Therapy

16:45-17:00 Discussion

17:00-17:15 Involving Patients in Oncology Drug Development

17:15-17:30 Discussion

17:30-17:45 The Use of Real-World Data to Optimize Oncology Drug Development and Access :

17:45-18:00 Discussion

19:00 Networking Dinner

DAY 2 - Tuesday 11 February 2020

Topic 3: TUMOR AGNOSTIC DRUG DEVELOPMENT (half-day) Rare diseases

- 09:00-09:45** **Medical aspects**
- 09:45-10:30** **Pharma-industry aspects**
- 10:30-11:00** **Coffee Break**
- 11:00-11:45** **Regulatory aspects**
- 11:45-12:30** **Discussion**
- 12:30-13:30** **Lunch**

Topic 4: CELL THERAPIES (incl. CART-T) (half-day)

- 13:30-14:15** **Progress in Haematological malignancies**
- 14:15-15:00** **Status in Solid tumors**
- 15:00-15:30** **Coffee Break**
- 15:30-16:15** **HTA issues**
- 16:15-17:00** **Regulatory aspects**
- 17:00-17:45** **Discussion**
- 19:00** **Networking dinner (off-site dinner)**

DAY 3 - Wednesday 12 February 2020

Topic 5: UPDATE ON NEW ANTICANCER GUIDELINE

- 09:00-09:45** **Speaker from EMA**
- 09:45-10:30** **Discussion (45 min)**
- 10:30-11:00** **CDDF Future Meetings**
- 11:00** **End of the Meeting & Lunch**